Page last updated: 2024-12-06

1-(9-fluorenyl)methyl chloroformate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-(9-Fluorenyl)methyl chloroformate, also known as Fmoc-Cl, is a widely used reagent in organic synthesis, particularly in peptide chemistry. It is employed for the protection of amine groups during peptide synthesis, enabling the selective modification and coupling of amino acids. Fmoc-Cl reacts with the amino group of an amino acid to form a stable carbamate derivative, known as an Fmoc-protected amino acid. This protection strategy is valuable because the Fmoc group can be easily removed under mild basic conditions, allowing for subsequent peptide chain elongation. The reagent's effectiveness stems from its high reactivity and its ability to form stable derivatives under mild conditions. Fmoc-Cl is commercially available and widely used in laboratories for various applications, including the synthesis of peptides, proteins, and other biologically active molecules.'

1-(9-fluorenyl)methyl chloroformate: used for tagging silica-based derivatization reagents in HPLC [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID34367
SCHEMBL ID27547
MeSH IDM0152765

Synonyms (60)

Synonym
(9h-fluoren-9-yl)methyl chloroformate
EN300-37269
formic acid, chloro-, fluoren-9-ylmethyl ester
einecs 249-313-6
fluoren-9-ylmethyl chloroformate
1-(9-fluorenyl)methyl chloroformate
ccris 2608
brn 2279177
9-fluorenylmethyl chloroformate
carbonochloridic acid, 9h-fluoren-9-ylmethyl ester
9h-fluoren-9-ylmethyl chloroformate
fmoc chloride, 97%
fmoc chloride
9h-fluoren-9-ylmethyl carbonochloridate
fmoc-cl
28920-43-6
(9h-fluoren-9-ylmethoxy)carbonyl chloride
chloroformic acid 9-fluorenylmethyl ester
F0197
AKOS009157869
(9h-fluoren-9-yl)methylcarbonochloridate
9-fluorenylmethyloxycarbonyl chloride
9-flourenylmethyl chloroformate
fmoc-chloride
9-fluorenylmethoxycarbonyl chloride
(9h-fluoren-9-yl)methyl carbonochloridate
9plb0btt90 ,
unii-9plb0btt90
FT-0621660
AM20040102
carbonochloridic acid 9h-fluoren-9-ylmethyl ester
9-fluorenylmethyl chloroformate [mi]
9-fluorenylmethylchloroformate
9-fluorenylmethyl chlorocarbonate
BP-21051
SCHEMBL27547
fmoccl
9-fluorenylmethyl chlorformate
9-fluorenylmethyl-chloroformate
9h-fluoren-9-ylmethylcarbonochloridate
9-fluoreneylmethyl chloroformate
9-fluorenylmethyoxycarbonyl chloride
9-fluorenemethyl chloroformate
9-fluorenyl-methyloxycarbonyl chloride
9-fluorenylmethoxycarbonyl-chloride
9h-fluoren-9-ylmethyl chloridocarbonate #
STR02408
Q-101295
AC-24425
mfcd00001138
DTXSID10183116
F0001-0905
fmoc chloride, bioreagent, >=99.0% (hplc)
fmoc chloride, for hplc derivatization, >=99.0% (hplc)
fmoc chloride, purum, >=98.0% (hplc)
C93459
9-fluorenylmethyl chloroformate; chloroformic acid 9-fluorenylmethyl ester
Q827647
fmoc-cl?chloroformic acid 9-fluorenylmethyl ester
fmoc-cl chloroformic acid 9-fluorenylmethyl ester

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Then, we synthesized estradiol-17 beta-succinate-(L-Asp)6 [E2-(L-Asp)6] and studied its pharmacokinetic characteristics and its antiosteoporotic effects on ovariectomized (OVX) mice."( Novel drug delivery system to bone using acidic oligopeptide: pharmacokinetic characteristics and pharmacological potential.
Higashi, Y; Kasugai, S; Masamune, Y; Miya, K; Miyamoto, K; Morito, K; Nitta, Y; Nomura, M; Sakura, N; Sawanishi, H; Sekido, T; Yokogawa, K, 2001
)
0.31

Compound-Compound Interactions

ExcerptReferenceRelevance
" In this study, we developed a new method to achieve the release, separation, and recovery of monomeric reducing N-glycans using enzyme E (Pronase E) combined with 9-chloromethyl chloroformate (Fmoc-Cl) and glycosylasparaginase (GA)."( Release, Separation, and Recovery of Monomeric Reducing N-Glycans with Pronase E Combined with 9-Chloromethyl Chloroformate and Glycosylasparaginase.
Huang, L; Jia, Y; Li, C; Lu, Y; Song, J; Wang, C; Wang, Z; Wei, M; Zhang, Y, 2019
)
0.51

Bioavailability

ExcerptReferenceRelevance
" In conclusion, this rapid and convenient analysis was found to be suitable for the bioavailability pharmacokinetic assessment of lidocaine following low-dose regional drug administration."( Sensitive high-performance liquid chromatographic assay using 9-fluorenylmethylchloroformate for monitoring controlled-release lidocaine in plasma.
Levy, RJ; Siden, R; Sintov, A, 1989
)
0.28

Dosage Studied

ExcerptRelevanceReference
" The developed method was applied to estimate PM quantitatively in two parenteral dosage forms."( Characterization, thermal stability studies, and analytical method development of Paromomycin for formulation development.
Khan, W; Kumar, N, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (151)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (6.62)18.7374
1990's44 (29.14)18.2507
2000's48 (31.79)29.6817
2010's44 (29.14)24.3611
2020's5 (3.31)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.94 (24.57)
Research Supply Index5.09 (2.92)
Research Growth Index5.03 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (2.55%)5.53%
Reviews1 (0.64%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other152 (96.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]